Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Global Cord Blood ( (CORBF) ) has shared an announcement.
On September 22, 2022, the Cayman Islands’ Grand Court appointed joint provisional liquidators for Global Cord Blood Corporation, due to ongoing disputes concerning the company’s register of members. The liquidators have sought court approval for fees incurred during the period from October 1, 2023, to September 30, 2024, as part of the necessary steps to manage the company’s provisional liquidation efficiently. Given the unresolved shareholder register issues, the liquidators are attempting to dispense with the need for an extraordinary general meeting. This situation reflects ongoing challenges in the company’s operations, affecting stakeholders’ ability to engage in decision-making processes.
More about Global Cord Blood
Global Cord Blood Corporation operates in the healthcare industry, focusing on the collection, storage, and research of umbilical cord blood. Their services primarily cater to families looking to preserve cord blood stem cells for potential future medical use.
Average Trading Volume: 6,917
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $132.6M
Find detailed analytics on CORBF stock on TipRanks’ Stock Analysis page.